Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
04:15pm, Wednesday, 04'th Dec 2024
DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m.
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , De
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
10:57am, Friday, 29'th Nov 2024
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
01:11pm, Thursday, 21'st Nov 2024
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
07:59pm, Wednesday, 20'th Nov 2024
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate a
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
04:05pm, Tuesday, 19'th Nov 2024
DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will pa
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
10:45am, Tuesday, 19'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
09:50am, Thursday, 14'th Nov 2024
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
01:06pm, Wednesday, 13'th Nov 2024
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 13'th Nov 2024
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
11:00am, Wednesday, 13'th Nov 2024
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
10:20am, Monday, 11'th Nov 2024
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
12:00pm, Thursday, 07'th Nov 2024
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
08:01pm, Wednesday, 06'th Nov 2024
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
